Table 4 Comparative analysis of pathological outcomes between 5-ARI and non-5-ARI groups in the TRUS/MRI fusion biopsy cohort and the subgroup of radical prostatectomy cohort.

From: The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging

N (%)

5-ARI group

Non-5-ARI group

P

Biopsy Gleason score

N = 29

N = 228

0.106

   6 = 3 + 3

6 (20.7%)

76 (33.3%)

 

   7 = 3 + 4

6 (20.7%)

72 (31.6%)

 

   7 = 4 + 3

7 (24.1%)

31 (13.6%)

 

   ≥8

10 (34.5%)

49 (21.5%)

 

Radical prostatectomy Gleason score

N = 19

N = 128

0.489

   6 = 3 + 3

0 (0)

4 (3.1%)

 

   7 = 3 + 4

7 (36.8%)

66 (51.6%)

 

   7 = 4 + 3

9 (47.4%)

44 (34.4%)

 

   ≥8

3 (15.8%)

14 (10.9%)

 

Gleason score upgrading

  

0.608

   No (N = 95)

11 (57.9%)

84 (65.6%)

 

   Yes (N = 52)

8 (42.1%)

44 (34.4%)

 
  1. 5-ARI, 5 alpha-reductase inhibitor.